Semaglutide: Difference between revisions

Line 22:

Neurological side effects, including headaches and dizziness, are also frequently reported. These may result from fluctuations in blood sugar levels and how the brain adjusts to changes in hunger and energy signaling. Other less direct effects, such as gastroenteritis, may occur due to altered gut motility or changes in gut flora, which increase susceptibility to infection. Additionally, semaglutide can affect kidney function because reduced fluid intake may lead to dehydration, highlighting the importance of monitoring hydration levels. Some users also report nasopharyngitis, potentially linked to immune modulation, though this is less common.

[[Image:Semaglutide side effects.png|600px]]

The bar chart depicts the proportion of patients experiencing common adverse events (AEs) during Phase 3a trials for semaglutide (0.5 mg and 1.0 mg) compared to other treatments, including exenatide ER and insulin glargine. The AEs include gastrointestinal disorders (nausea, vomiting, diarrhea, constipation), nasopharyngitis, fatigue, and headache. Data are presented as adjusted percentages, with odds ratios (OR) and confidence intervals (CI) providing additional context. OR values above 1.0 suggest a higher likelihood of AEs with semaglutide, while CIs indicate the range of variability and precision. The results show that semaglutide, particularly at the 1.0 mg dose, is associated with a higher frequency of gastrointestinal AEs compared to comparators. Neurological side effects, such as headache and fatigue, and nasopharyngitis were also more common in semaglutide groups. These findings underscore the dose-dependent nature of AEs with semaglutide and the importance of balancing its efficacy in weight loss with patient tolerability.<ref>Committee for Medicinal Products for Human use (CHMP). European Medicines Agency (EMA). (2018).

https://www.ema.europa.eu/en/documents/assessment-report/ozempic-epar-public-assessment-report_en.pdf</ref>

While semaglutide is effective for weight loss, these findings emphasize the need to balance therapeutic benefits with patient tolerability, tailoring treatment plans to minimize side effects while achieving optimal outcomes.

Semaglutide: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 22: / Line 22: @@
 Neurological side effects, including headaches and dizziness, are also frequently reported. These may result from fluctuations in blood sugar levels and how the brain adjusts to changes in hunger and energy signaling. Other less direct effects, such as gastroenteritis, may occur due to altered gut motility or changes in gut flora, which increase susceptibility to infection. Additionally, semaglutide can affect kidney function because reduced fluid intake may lead to dehydration, highlighting the importance of monitoring hydration levels. Some users also report nasopharyngitis, potentially linked to immune modulation, though this is less common.
+[[Image:Semaglutide side effects.png|600px]]
+The bar chart depicts the proportion of patients experiencing common adverse events (AEs) during Phase 3a trials for semaglutide (0.5 mg and 1.0 mg) compared to other treatments, including exenatide ER and insulin glargine. The AEs include gastrointestinal disorders (nausea, vomiting, diarrhea, constipation), nasopharyngitis, fatigue, and headache. Data are presented as adjusted percentages, with odds ratios (OR) and confidence intervals (CI) providing additional context. OR values above 1.0 suggest a higher likelihood of AEs with semaglutide, while CIs indicate the range of variability and precision. The results show that semaglutide, particularly at the 1.0 mg dose, is associated with a higher frequency of gastrointestinal AEs compared to comparators. Neurological side effects, such as headache and fatigue, and nasopharyngitis were also more common in semaglutide groups. These findings underscore the dose-dependent nature of AEs with semaglutide and the importance of balancing its efficacy in weight loss with patient tolerability.<ref>Committee for Medicinal Products for Human use (CHMP). European Medicines Agency (EMA). (2018).
+https://www.ema.europa.eu/en/documents/assessment-report/ozempic-epar-public-assessment-report_en.pdf</ref>
 While semaglutide is effective for weight loss, these findings emphasize the need to balance therapeutic benefits with patient tolerability, tailoring treatment plans to minimize side effects while achieving optimal outcomes.